Amphastar Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.3 Mil. Amphastar Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $619.3 Mil. Amphastar Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $639.4 Mil.
Amphastar Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.98.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Amphastar Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
AMPH'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12 Med: 0.16 Max: 0.98
Current: 0.98
During the past 13 years, the highest Debt-to-Equity Ratio of Amphastar Pharmaceuticals was 0.98. The lowest was 0.12. And the median was 0.16.
Amphastar Pharmaceuticals Debt-to-Equity Historical Data
The historical data trend for Amphastar Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Amphastar Pharmaceuticals Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
0.18 |
0.17 |
0.24 |
0.19 |
0.98 |
|
Amphastar Pharmaceuticals Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.19 |
0.19 |
0.90 |
1.13 |
0.98 |
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Debt-to-Equity Distribution
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Debt-to-Equity falls into.
Amphastar Pharmaceuticals Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Amphastar Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Amphastar Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description
Traded in Other Exchanges
Address
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Executives
| Mary Z. Luo |
director, 10 percent owner, officer: COO and Chief Scientist |
11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
| Floyd F. Petersen |
director |
11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
| Rong Zhou |
officer: EVP, Production |
C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730 |
| Richard K Prins |
director |
|
| William J Peters |
officer: CFO, SVP & Treasurer |
C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
| Yakob Liawatidewi |
officer: SVP Corp Admin Center |
C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730 |
| Michael A Zasloff |
director |
|
| Gayle Deflin |
director |
11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
| Diane G. Gerst |
officer: EVP, QA & Regulatory Affairs |
11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
| Howard Lee |
director |
13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000 |
| Jack Y. Zhang |
director, 10 percent owner, officer: CEO & Chief Scientific Officer |
11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
| David Maris |
director |
C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
| Richard Koo |
director |
11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
| Jason B. Shandell |
director, officer: President |
11570 6TH STREET, RANCHO CUCAMONGA CA 91730 |
| Applied Physics & Chemistry Laboratories, Inc. |
10 percent owner |
13760 MAGNOLIA AVENUE, CHINO CA 91710 |
Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMPH has been successfully added to your